Fulcrum Therapeutics announced it stopped development of its sickle cell disease drug, pociredir, following FDA concerns about cancer risks linked to similar drugs. This led to a 51% drop in its stock price. Kaplan Fox & Kilsheimer LLP is investigating potential securities violations related to this event. Investors who suffered losses or have relevant information are encouraged to contact the law firm for possible legal action.
Kaplan Fox's investigation of Fulcrum Therapeutics for possible securities law violations is the subject here, with Pluang's Health sector data providing market context. For readers following Health stocks, as of Sep 23, 2026 05:11 WIB, 69 of 101 priced US Health-sector stocks on Pluang rose while 32 fell. Notable movers include DGX at USD 232.90 with a -5.51% change and 0% Sell / 100% Buy order activity, Moderna (MRNA) at USD 182.46 up 5.50% with 67% Sell / 33% Buy, and Canopy Growth (CGC) at USD 0.97 up 4.85% with 0% Sell / 100% Buy.
BMO Capital initiated coverage on Tenet Healthcare with a 'Market Perform' rating, indicating the stock is expected to perform in line with the broader market. The company is forecasted to report a 24.05% increase in Earnings Per Share (EPS) to $4.59...
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...
Jefferies maintains a Hold rating on Capri Holdings due to uncertainty over a potential takeover. Despite a flat global luxury market, Capri's management expects growth in the second half of 2026, driven by new product launches, increased marketing, ...
Avalanche (AVAX) surged 55% in a week following the launch of Bitwise's Avalanche ETF (BAVA), the first regulated fund offering direct exposure to AVAX tokens with an active staking model. The ETF stakes about 70% of its holdings to generate an estim...
